Navigation Links
Positron Finalizes Acquisition of Manhattan Isotope Technology, LLC
Date:1/17/2012

FISHERS, Ind., Jan. 17, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce the acquisition of Manhattan Isotope Technology, LLC (MIT).  Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3,500,000 based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.

Positron, through its wholly owned subsidiary MIT, is the only commercial resource in the United States with practical knowledge and experience in all stages of strontium-82 (Sr-82) production, and spent generator lifecycle management.  Positron will focus on increasing Sr-82 supply through the processing of proton irradiated target material from domestic & foreign suppliers and recycling Sr-82 from spent generators.  MIT seeks to become the first supplier to provide Active Pharmaceutical Ingredient (API) grade Sr-82 in the U.S. besides the United States Department of Energy.  In an effort to expand Positron's radioisotope product offerings, MIT possesses the unique and specialized expertise in the production of additional radioisotopes, such as germanium-68, selenium-72 and others, which are currently only supplied by the U.S. Government. 

In pursuit of securing a proprietary supply of radioisotopes for cardiac PET imaging, Positron plans to build and operate the world's largest commercial high energy/high current cyclotron (70MeV) in the U.S.  With the addition of MIT, Positron gains the ability to develop internal processing capabilities, gain regulatory approvals and establish a broad multiple product customer base further enhancing the timeliness of launch and long term value of this project.  Positron's planned cyclotron facility, once completed, will become the workhorse of high energy radioisotope production in North America, providing a reliable, secure, indigenous supply of radioisotopes therefore stabilizing and building confidence throughout the cardiac PET market and nuclear medicine community overall.  Positron is committed to advancing the practice and technology of Nuclear Cardiology and with our integrated solution will play the largest role in the future and longevity of the industry.

Commenting upon the significance of the new company, MIT President Jason Kitten stated, "The staff at MIT brings decades of combined experience in isotope manufacturing and high consequence radiological facility engineering and design. With Positron's vertically integrated approach and foresight in developing a robust solution to the isotope supply limitations, Positron is well positioned to become a total solutions provider expanding the U.S. market while taking its total solution strategy global."

About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology.  Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine.  Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

 

 


'/>"/>
SOURCE Positron Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positron Recieves Indiana Board of Pharmacy License
2. Positrons Attrius Receives Health Canada Approval
3. Published Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT
4. National Institute of Cancer Is the First Center in Mexico to Offer Positron Emission Mammography
5. Study Validates Clinical Accuracy of 50% Dose Reduction for Positron Emission Mammography
6. Study Shows Positron Emission Mammography (PEM) is Easy for Breast Imagers to Learn Regardless of Experience
7. Naviscan Announces European Launch of Positron Emission Mammography
8. Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015
9. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
10. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
11. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Future published a Half Cooked Research Report on Endoscopy Devices Market. ... million during the period 2016 to 2022 from USD 28.7 million ... ... as a swiftly growing market and expected to grow at a ... various regions.  The increasing growth in endoscopy procedures is influencing the ...
(Date:1/17/2017)... 17, 2017 Research and Markets has announced ... 2016-2020" report to their offering. ... The global fluoropolymer market in the healthcare ... 2016-2020. Global Fluoropolymer Market in the Healthcare Industry ... inputs from industry experts. The report covers the market landscape and ...
(Date:1/17/2017)...   Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, ... research and pharmaceutical development at Tocagen, will present at Phacilitate ... 17-20 in Miami . Details ... ... replicating viruses - what to do when and why Date and ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s ... honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD ... elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by the ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... joined the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based ... Medical Center is an exciting addition to our provider network, and the addition ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Neil H. ... financial planning assistance to communities throughout the region, is launching a charity drive to ... disease is by far the deadliest killer in America, and is responsible for 1 ...
(Date:1/17/2017)... ... 2017 , ... SC&H Group, a leading audit, tax, and consulting firm, announced ... Advisory Services practice . Rossi is the third technology consulting leader to join SC&H ... grows, and the practice continues to expand.     , Bringing more than 25 years of ...
Breaking Medicine News(10 mins):